Kornimate/medical-research-clean huggingface dataset:
enabling genomic testing in cancer of unknown primary

Conditions: Cancer of Unknown Primary; Neoplasm, Unknown Primary

Summary: cancer of unknown primary (cup) is where cancer cells are found in the body but the place the cancer began is not known. it is the 6th leading cause of cancer death in the uk and the prognosis is poor with a median survival of 6-9 months. there is a higher than average incidence of cup in the north west (nw) of england (population of 7.4 million). precision medicine has transformed treatment strategies in known tumour types, however in cup there remains an urgent need to better understand cup molecular characteristics to establish potential roles for novel therapeutic strategies. treatment options remain limited due to difficulties in determining the primary site of the tumour and the lack of access to validated biomarkers. access to good-quality tissue for molecular profiling remains a huge challenge in cup. the emergence of liquid biopsies (sequence dna in a blood test) as a source of biomarkers is also gaining rapid ground and this study aims to explore the potential utility of liquid biopsies in cup.


Eligibility criteria:
inclusion criteria: 1. aged 16 years or over 2. written informed consent according to ich/gcp and national regulations 3. ecog performance status 0-2 4. confirmed diagnosis of cup as per the esmo guidelines. patients must have; 1. the local pathology reports confirming compatibility with cup diagnosis and the associated slides used for the diagnosis 2. discussion at a local cup mdt confirming diagnosis 5. availability of archival tumour histological report 6. willingness to provide blood samples on up to two occasions during the study exclusion criteria: 1. patient with an immunohistochemistry profile that provides a definitive clinical indication of a primary cancer with a specific treatment 2. known hiv, hepatitis b, c positive, due to the difficulties in handling high-risk specimens 3. patients who are unable to provide fully informed written consent 4. presence of any medical, psychological, familial or sociological condition that, in the investigator's opinion, will hamper compliance with the study protocol and follow-up schedule 5. bleeding diathesis (patients' on anticoagulation are permitted to enter the trial if anticoagulation can be safely managed to enable blood sampling) 6. conditions in which blood sampling may increase risk of complications for the patients and/or investigator

Keywords: cancer of unknown primary cancer
comparison of pvi and rpvi

Conditions: Venous; Return (Anomaly)

Summary: pleth variability index (pvi) is a non-invasive and automated measure of the respiratory variations of plethysmography during mechanical ventilation. pvi is extracted via an algorithm implemented on masimo radical 7 device (masimo, irvine, ca). pvi is commonly used in anesthesiology and has been validated to predict fluid responsiveness and optimize fluid administration in the surgical setting. however, the signal/noise ratio of pvi makes acute changes in pvi somewhat difficult to interpret at the bedside. subsequently, a new algorithm entitled rpvi (rainbow pleth variability index), has been developed in order to improve the signal/noise ratio of pvi and facilitate its clinical use by practitioners. the details of this new proprietary built-in algorithm are unknown and no data are available to date. therefore, the main objective of the study was to compare rpvi and pvi during dynamic changes in venous return induced by a tidal volume (vt) challenge during mechanical ventilation in anesthetized patients. the hypothesis was that the agreement between both dynamic indices would be good.


Eligibility criteria:
inclusion criteria: * age \> 18 * low or intermediate risk surgery or noninvasive procedures in the supine position * general anaesthesia and volume-controlled mechanical ventilation. exclusion criteria: * non sinus heart rhythm * left ventricular ejection fraction \< 50% * documented right ventricle failure * lack of patient consent * pregnancy * minor patient or under tutorship * presence of spontaneous ventilatory movements (attested by a real respiratory rate higher than the set respiratory rate) * report hr / rr \<3.6 (hr: heart rate, rr: respiratory rate) * open chest surgery * laparoscopic surgery * vital or lateral decubitus surgery
digest i drug coated balloon for biliary stricture

Conditions: Biliary Stricture; Biliary Anastomotic Stenosis; Biliary Obstruction; Biliary Disease

Summary: digest i pilot study is a feasibility study for evaluating the safety and efficacy of dcbs.

the study is designed to determine the safety and effectiveness of drug coated balloon (dcb) treatments on biliary tract stricture. up to 15 subjects are planned to be enrolled and treated with the study device at up to 5 clinical sites outside of us. subjects will be followed up post-treatment to one year and then annually for up to 5 years. the annual follow up after the first year is optional.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 and ≤ 80 years. 2. benign biliary stricture with postoperative injury or psc or anastomotic-stricture; and indicated for ercp procedure. 3. restenosis after plain balloon dilation with at least 2 previous balloon dilation sessions and recurrence of biliary obstructive symptoms/signs or being managed with implantable prosthetics (e.g. plastic stents). 4. greater than 40% stenosis of the biliary tract via ercp. 5. total serum bilirubin \>2 mg/dl. alkaline phosphatase level \>3 times higher than normal level. \*note: this ic is waved if the patient is being managed with implantable prosthetics. 6. type i, ii, iii and iv benign biliary duct strictures. dominant stricture being accessible by balloon catheter. 7. stricture length \<4 cm. 8. not currently listed for liver transplantation. 9. voluntary participation and provided written informed consent. exclusion criteria: 1. pregnancy or breastfeeding or plan to get pregnant in next 12 months. 2. benign biliary strictures caused by pancreatic pseudocyst compression. 3. malignant biliary obstruction. 4. biliary obstruction associated with an attack of acute pancreatitis. 5. inability to pass guidewire across stricture. 6. subjects with cholangitis or bile leak or duct fistula. 7. contraindication for endoscopic retrograde cholangiopancreatography (ercp) or anesthesia or deep sedation or mri. 8. subject with an internal/external biliary drainage catheter. 9. subjects with surgically altered gastro/duodenal/jejunal anatomy (e.g. roux-y-loop, choledochojejunostomy). 10. subject with symptomatic duodenal stenosis (with gastric stasis) 11. active systemic infection. 12. allergy to paclitaxel or any components of the delivery system. 13. currently undergoing required thoracic or abdominal cavity radiation therapy. 14. has life expectancy \<12 months. 15. unwilling or unable to comply with the follow-up study requirements. 16. lacking capacity to provide informed consent. 17. concurrent medical condition that would affect the investigator's ability to evaluate the patient's condition or could compromise patient safety. 18. currently participation in another pre-market drug or medical device clinical study.
peg interferon α-2b for relapsed hematological malignancies after allo-hsct

Conditions: Hematological Neoplasms; Recurrence

Summary: aim: to observe the graft versus tumor effect of pegylated interferonα-2b in patients with hematological malignancies relapsed after allogeneic hematopoietic stem cell transplantation (allohsct) patients: patients relapsed after allohsct, men and women aged 14-60 years, without vital organ dysfunction or ongoing graft-verus-host disease (gvhd). number of subjects: 50, single center, one group, prospective. drug: pegylated interferon alpha-2b (peg intron®; schering-plough) 1\~1.5ug/kg qw, until occurrence of grade ii or higher grade of acute gvhd, or no response to treatment after 8 doses of treatments.

eligible patients were age 14 to 60 years with molecular, hematological or radiography relapsed hematological malignancies post allogeneic hematopoietic stem cell transplantation. molecular relapse was defined as reappearance or 1 log increase of molecular markers or decreasing donor chimerism by more than 5%; hematological relapse was defined as reappearance of blast in bone marrow smear by more than 5%; radiography relapse was defined as enlargement of lymph nodes by more than 25% or infiltration of tumor cells in other sites. patients were excluded if they need immunosuppressant treatment for ongoing grade ii～iv acute gvhd or moderate to severe chronic gvhd. eligible patients were treated with pegylated interferon alpha-2b (peg intron®; schering-plough (brinny) company, innishannon, county cork, ireland) 1\~1.5ug/kg qw, until occurrence of grade ii or higher grade of acute gvhd, or no response to treatment after 8 doses of treatments. patients were followed up every week. physical exams and blood tests including complete blood count (cbc), chemical were performed every week. disease status evaluation was performed every month. number of subjects: 50 single center, one group, prospective.

Eligibility criteria:
inclusion criteria: 1. age 14-60 years, male or female 2. allo-hsct recipients with malignant hematological diseases 3. disease relapse after allo-hsct, including hematological relapse, molecular relapse 4. able to provide written informed consent and to comply with all study procedures exclusion criteria: 1. pregnant or nursing woman 2. cardiac ejection factor \< normal lower limit 3. active acute or chronic gvhd with immunosuppressant treatment 4. known hypersensitivity or allergy to interferon 5. patient might develop serious complications according to investigator's experiences 6. patient is undergoing other experimental medication

Keywords: hematological neoplasms recurrence hematopoietic stem cell transplantation peginterferon alfa-2b graft vs host disease
role of color doppler ultrasound in lymphadenopathy

Conditions: Lymph Node Disease

Summary: lymphadenopathy is defined as an abnormality in the size or character of lymph nodes caused by the invasion or propagation of either inflammatory or neoplastic cells into the nodes accurate lymph node characterization is important for a wide number of clinical situations, including prognosis, prediction, selecting and monitoring treatment, beyond the diagnosis itself (cancer, lymphoma, or inflammatory nodes)

various ultrasound criteria that can help in differentiation of benign and malignant lymph nodes have been well described in literature. on gray scale ultrasound imaging, the benign enlarged lymph nodes are hypoechoic, oval shaped with smooth border and echogenic hilum. on the other hand, the malignant lymph nodes are round with short to long axis ratio \>0.5 and show loss of echogenic hilum, while the color and power doppler features documented for the diagnosis of malignant lymph nodes are peripheral and mixed vascularity, with resistive index (ri) more than 0.8, and pulsatility index (pi) more than 1.5 although color doppler ultrasound improves diagnostic accuracy and plays an important adjuvant role to gray scale ultrasound in differentiating benign from malignant lymph nodes as it adds to the diagnostic confidence of predicting malignancy in enlarged lymph nodes, and also is useful if gray scale ultrasound findings are equivocal. however, it can neither replace histopathology nor can eliminate the need for biopsy

Eligibility criteria:
inclusion criteria: * clinically enlarged lymph nodes exclusion criteria: * previous medical treatment or radiotherapy * previous biopsy
use of bevacizumab in trabeculectomy surgery

Conditions: Glaucoma; Optic Neuropathy; Fibrosis

Summary: when a patient with glaucoma who has a pressure that is too high and causing damage to their vision, despite receiving the maximum amount of medication that can be tolerated, the decision is made to have glaucoma surgery. trabeculectomy is the most common form of glaucoma surgery used to treat open angle glaucoma. during trabeculectomy, an opening is created in the eye and partially covered with a flap of tissue. this new opening allows fluid to drain out of the eye bypassing the clogged drainage channels that are malfunctioning in patients with glaucoma. studies have found that trabeculectomy significantly reduces vision loss and lowers eye pressure. however, many people need another trabeculectomy or other glaucoma surgery because the surgery may fail either early or much later because the body closes the drain created by the surgeon. the surgery is also less likely to work in patients with darker pigmentation, children who have congenital glaucoma, people with difficult to control glaucoma with new blood vessels growing on the iris, diabetes or persons with prior eye surgery. as a result, the investigators need to find ways to improve the longterm survival of trabeculectomy surgery in all patients.

the usual treatment is to not have an injection of bevacizumab on the third through fifth day after trabeculectomy surgery. topical anaesthetic drops to numb the eye will be given, prior to being given the tested medicine. once the eye has been anaesthetized, the medication will be injected into the potential space created during the glaucoma surgery, also called a bleb, using a standard small syringe. the patient will receive an injection of either 1.25mg (0.05ml) of bevacizumab or balanced salt solution (bss) into the trabeculectomy bleb that had been created in the surgery. participants will be randomly (by chance) placed in one of the 2 study groups. there will be a 50% chance of being placed in either group. there will be 60 people who will participate in this study at 2 centres throughout the toronto region. the length of this study for participants is 12 months, and the entire study is expected to take about 18 months to complete.

Eligibility criteria:
inclusion criteria: * age more than 18 years old * patients with glaucoma that is inadequately controlled on maximal tolerated medical therapy and scheduled for trabeculectomy surgery (with/without combined cataract extraction) * decision makers fluent in english * decision makers able to understand and read consent form exclusion criteria: * patients with active intraocular inflammation/uveitis or neovascular glaucoma * history of previous trabeculectomy surgery or prior retinal detachment with scleral buckle placement in the surgical eye * aphakia in surgical eye * pregnant and nursing women * unable to fulfill inclusion criteria * refusal of consent

Keywords: glaucoma elevated intraocular pressure (iop) optic neuropathy bleb failure avastin (bevacizumab)
measurement of renal functional reserve change in patients with src before and after laparoscopic deroofing

Conditions: Simple Renal Cyst

Summary: renal functional reserve may be improved in patients with simple renal cysts after laparoscopic deroofing.

simple renal cysts (src) are the most frequent type of cystic renal disease. the prevalence rate of srcs is about 10% and increases with age. hypertension and decreased renal functions have been reported to occur more commonly among these patients with src and there are no clear guidelines for managing asymptomatic srcs.renal functional reserve (rfr) describes the capacity of the intact nephron mass to increase glomerular filtration rate(gfr) from baseline in response to stimuli (e.g., protein load).the investigators hypothesized that rfr may be improved in some patients with simple renal cysts after laparoscopic deroofing despite identical resting glomerular filtration rate (rgfr).the aim of this study is to examine whether there is improvement of rfr in patients with simple renal cysts after laparoscopic deroofing.

Eligibility criteria:
inclusion criteria: 1. age ≥18 2. estimated gfr \>30 ml/min/1.73m2 3. subjects who signed informed consent forms exclusion criteria: 1. allergy to iothalamate, shellfish or iodine 2. use of metformin or amiodarone 3. inability to maintain a stable regimen of medications which affect gfr for \> one week prior to participation (e.g. non-steroidal anti-inflammatory drugs, angiotensin converting enzyme inhibitors, angiotensin receptor blockers) 4. use of medications which directly affect elimination of creatinine (e.g. cimetidine and trimethoprim) 5. acute exacerbation of asthma or chronic obstructive pulmonary disease within 3 months requiring hospitalization or oral steroid therapy 6. inadequate intravenous access 7. severe anemia (hct \<21%) 8. acute kidney injury (rise in creatinine to ≥1.5 times the previous baseline or by ≥ 0.3 mg/dl on most recent labs prior to enrollment) 9. history of contrast-induced nephropathy 10. hyperthyroidism 11. pheochromocytoma 12. sickle cell disease 13. urinary retention or incontinence 14. status post organ transplant 15. pregnancy or active breast feeding 16. cognitive impairment with inability to give consent 17. institutionalized status

Keywords: renal functional reserve simple renal cysts laparoscopic deroofing
movement-based pelvic health education for women in underserved communities

Conditions: Pelvic Floor Muscle Weakness; Pelvic Pain

Summary: it is essential to provide the community with evidenced-based care to optimize healthcare outcomes; more specifically, women in underserved communities undergoing health disparities in rehabilitation. to address this issue, a movement-based pelvic health education course was developed to assess women's knowledge and adherence of the exercises in an underserved region in western arkansas.the purpose of this research was to determine the effectiveness of a single movement-based pelvic health education session on general pelvic health knowledge, underactive pelvic floor, and overactive pelvic floor knowledge and adherence to performing pelvic exercises in women.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * female-identifying * ability to speak english or provide own translator * ability to complete the questionnaires * clearance from physician if pregnant * access to internet exclusion criteria: -experiencing pelvic pain and/or pregnant and does not have physician clearance to participate

Keywords: women's health community education underserved population
new echocardiographic methods for right ventricular function.

Conditions: Right Ventricular Dysfunction

Summary: aims of this study are the evaluation of new echocardiographic methods (3d/4d- and strain-echocardiography) for measurement of the right ventricular (rv) function .

studies of the last years revealed that the right ventricular function is an important predictive value for the survival of patients with congenital heart disease, pulmonary hypertension or chronic heart failure. in 2006 the national heart, lung and blood institute has pronounced the right ventricular dysfunction including the non-invasive assessment of the right ventricular function as preferential aim of cardiovascular research. many parameters are used to describe right ventricular dysfunction, but none of these has a comparable significance like the left ventricular ejection fraction. because of the limitation of each right ventricular parameter the stepwise combination of these parameters is used to describe right ventricular function what frequently results in further problems, especially in comparison of long-term controls. aims of this study are the evaluation of new echocardiographic methods (3d/4d- and strain-echocardiography) for measurement of the right ventricular (rv) function. the study is carried out as prospective, monocentric trial at the department of cardiology of the university hospital of heidelberg. three different groups are set up for the assessment of the right ventricular function: patients with pulmonary arterial hypertension, patients with chronic heart failure of the left ventricle affecting the right heart and patients without structural heart disease who underwent an echocardiographic examination for other reasons (control group). all participants are re-examined in constant intervals as clinically indicated.

Eligibility criteria:
inclusion criteria: * persons of 18 years and older who receive a transthoracic echocardiography at our department * written consent exclusion criteria: * present atrial fibrillation/flutter * permanent pacemaker rhythm * moderate/severe valvular heart disease * pregnancy

Keywords: echocardiography of the right heart 3d 4d echocardiography strain measurement chronic heart failure pulmonary hypertension
to describe how well vinorelbine given orally works in patients with a breast cancer after 2 years of treatment

Conditions: Advanced Breast Cancer

Summary: this study looks at how well oral vinorelbine works in treating advanced breast cancer. it looks at women who have already had this treatment or are currently having it.

this is an international, multicenter, retrospective and prospective, observational study. the study will comprise of two cohorts: * retrospective: patients who started ov treatment for abc between 2011 and 2020 will be enrolled in the retrospective cohort study. the observation period for retrospectively included patients will extend from the initiation of ov treatment to the date of death, date of last contact or end date of retrospective observation period, whichever occurs first. the end date of retrospective observation period will be set as the date of the inclusion of the first patient in the study (first patient in= fpi). * prospective: patients initiating ov treatment and eligible for prospective collection of qol data and ppq and wpai questionnaires will be enrolled in the prospective cohort study. the enrollment period is expected to extend up to 17 months from study start. the study observation period will extend up to 2 years after last patient first visit (around 24 months after treatment initiation). due to the observational nature of this study, no additional medical procedures or in person clinical visits beyond routine oncology care will be required for this study.

Eligibility criteria:
inclusion criteria: female aged ≥ 18 years (≥ 19 years for algeria as per local regulation) at oral vinorelbine ( ov) -based treatment initiation confirmed diagnosis of locally advanced or metastatic breast cancer eligible for chemotherapy initiated ov-based treatment as per smpc for advanced breast cancer between january 2011 and december 2020 for the retrospective cohort or, initiating oral vinorelbine treatment at enrollment for the prospective cohort willing and able to complete the qol questionnaire, ppq and wpai questionnaire for the prospective cohort provision of informed consent or non-opposition to the patient (or next of kin/legal representative, if applicable) for the use of data, according to local regulations exclusion criteria: no exclusion criteria for patients in this study